ArticleFrontiers in immunology2022
Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- HPV42 - a human papillomavirus classified as a low-risk type with oncogenic potential.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Review
- The human skin virome: Ecological dynamics, aberrant profiles, and therapeutic opportunities.Cell host & microbe · 2026Review
- Review
- Innovations in HPV vaccination and their role in global cervical cancer control: a review.Therapeutic advances in vaccines and immunotherapy · 2026Review
- Proteome-wide curation of experimentally validated HPV T-cell epitopes identifies key gaps in our understanding of cellular immunity to HPV and informs vaccine design.Frontiers in immunology · 2026Article
- Review
- Non-melanoma skin cancer and HPV in persons with albinism: a call for research investment.British journal of cancer · 2025Review
- Assessment of the ability of HPV vaccines to induce neutralizing antibodies based on pseudovirus-based neutralization assay.Frontiers in public health · 2025Article
- Review
- mRNA vaccines as cancer therapies.Chinese medical journal · 2024Review
- Article
- BRAF Inhibition and UVB Light Synergistically PromoteCancers · 2024Article
- Article
- Inter-epitope spacer variation within polytopic L2-based human papillomavirus antigens affects immunogenicity.NPJ vaccines · 2024Article
- A comprehensive narrative review of challenges and facilitators in the implementation of various HPV vaccination program worldwide.Cancer medicine · 2024Review
- Diversity and independent evolutionary profiling of rodent-borne viruses in Hainan, a tropical island of China.Virologica Sinica · 2023Article
- Prevention and Treatment of HPV-Induced Skin Tumors.Cancers · 2023Review
- Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Licensed L1-VLP-based immunizations against high-risk mucosal human papillomavirus (HPV) types have been a great success in reducing anogenital cancers, although they are limited in their cross-protection against HPV types not covered by the vaccine. Further, their utility in protection against cutaneous HPV types, of which some contribute to non-melanoma skin cancer (NMSC) development, is rather low. Next generation vaccines achieve broadly cross-protective immunity against highly conserved sequences of L2. In this exploratory study, we tested two novel HPV vaccine candidates, HPV16 RG1-VLP and CUT-PANHPVAX, in the preclinical natural infection model
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.